Emboline Secures $20M for Emboliner US-EU Launch After IDE Trial
Emboline raised $20m from sole investor Trinity Capital, boosting total funds to $93m for its Emboliner cerebral protection device used in TAVR procedures. After completing an IDE trial and planning a March 29 data presentation, Emboline targets US and EU commercial launches this year, positioning Trinity Capital to profit from sales.
1. Funding and Investor Details
Emboline secured a $20 million funding tranche from its sole investor, Trinity Capital, bringing total capital raised to approximately $93 million. These funds will support continued development and regulatory activities for the Emboliner embolic protection system designed for TAVR.
2. Clinical Trial Milestone
The company has completed its IDE clinical trial (NCT05684146) for Emboliner and will present safety and efficacy data at the American College of Cardiology conference on March 29, advancing its regulatory submission timeline.
3. Commercial Launch Strategy
Emboline plans to launch Emboliner in the US and Europe this year, positioning it against competing devices like Boston Scientific’s SENTINEL and aiming to capture market share in the growing transcatheter heart valve sector.